2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow Keratosis palmoplantaris papulosa: new trials by email Literature Review of Keratosis palmoplantaris papulosa trials Research Report on Keratosis palmoplantaris papulosa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC KM-001 cream 1% 12 weeks treatment., Physical Examination, Vital Signs - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 18 | 2023-03-06 | 2025-01-15 |
| Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases Serum chemistry, Hematology, Urinalysis - Punctate Palmoplantar Keratoderma Type 1, Pachyonychia Congenita | Phase 1 | Completed | Orvida Pharma (formerly Kamari Pharma) | 14 | 2022-07-17 | 2025-01-07 |
Abnormalities, Multiple (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Ectodermal Dysplasia (2) · Genetic Diseases, Inborn (2) · Nail Diseases (2) · Skin Abnormalities (2) · Skin Diseases (2) · Skin Diseases, Genetic (2) · Skin and Connective Tissue Diseases (2)
Hematologic Tests (2) · Pain Measurement (2) · Physical Examination (2) · Therapeutics (2) · Urinalysis (2) · Vital Signs (2) · KPNA1 protein, human (1)
Orvida Pharma (formerly Kamari Pharma) (2)
Israel (1) · United Kingdom (1)